StockData
Anixa Biosciences Inc logo

Anixa Biosciences Inc (ANIX) stock

ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 5/30
$2.67+0.12 (+4.71%)

Close on Nov 17, 2026Market cap $92.82MP/E –Yield –

Anixa Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Anixa Biosciences's R&D Expenses for the twelve months ending Jul 31, 2026 was $4.83M, down 10.7% year over year. For fiscal 2025 it was $5.07M, down 20.7% from the year before. Over ten years it grew 21.7% a year on average. The highest annual figure on record is $6.81M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Oct 31, 2025$5.07M-20.7%
FY2024Oct 31, 2024$6.40M+34.1%
FY2023Oct 31, 2023$4.77M-28.9%
FY2022Oct 31, 2022$6.70M+8.3%
FY2021Oct 31, 2021$6.19M+41.3%
FY2020Oct 31, 2020$4.38M-20.0%
FY2019Oct 31, 2019$5.47M-19.7%
FY2018Oct 31, 2018$6.81M+326.5%
FY2017Oct 31, 2017$1.60M+2.6%
FY2016Oct 31, 2016$1.56M+118.8%
FY2015Oct 31, 2015$711.39K-67.8%
FY2012Oct 31, 2012$2.21M-29.2%
FY2011Oct 31, 2011$3.12M+3.9%
FY2010Oct 31, 2010$3.01M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jul 31, 2026$1.33M+25.7%
Q2 FY2026CQ1 2026Apr 30, 2026$1.26M-4.8%
Q1 FY2026CQ4 2025Jan 31, 2026$1.10M-29.0%
Q4 FY2025CQ3 2025Oct 31, 2025$1.14M-22.6%
Q3 FY2025CQ2 2025Jul 31, 2025$1.06M-45.2%
Q2 FY2025CQ1 2025Apr 30, 2025$1.32M-19.7%
Q1 FY2025CQ4 2024Jan 31, 2025$1.55M+15.0%
Q4 FY2024CQ3 2024Oct 31, 2024$1.48M-8.6%
Q3 FY2024CQ2 2024Jul 31, 2024$1.93M+76.9%
Q2 FY2024CQ1 2024Apr 30, 2024$1.65M+64.9%
Q1 FY2024CQ4 2023Jan 31, 2024$1.35M+26.3%
Q4 FY2023CQ3 2023Oct 31, 2023$1.62M-4.2%
Q3 FY2023CQ2 2023Jul 31, 2023$1.09M-24.7%
Q2 FY2023CQ1 2023Apr 30, 2023$998.00K-42.5%
Q1 FY2023CQ4 2022Jan 31, 2023$1.07M-41.9%
Q4 FY2022CQ3 2022Oct 31, 2022$1.69M-22.5%
Q3 FY2022CQ2 2022Jul 31, 2022$1.45M-33.3%
Q2 FY2022CQ1 2022Apr 30, 2022$1.74M+69.8%
Q1 FY2022CQ4 2021Jan 31, 2022$1.84M+122.0%
Q4 FY2021CQ3 2021Oct 31, 2021$2.17M+433.0%
Q3 FY2021CQ2 2021Jul 31, 2021$2.17M+72.8%
Q2 FY2021CQ1 2021Apr 30, 2021$1.02M-16.8%
Q1 FY2021CQ4 2020Jan 31, 2021$828.00K-44.5%
Q4 FY2020CQ3 2020Oct 31, 2020$407.70K-53.2%
Q3 FY2020CQ2 2020Jul 31, 2020$1.25M+15.5%
Q2 FY2020CQ1 2020Apr 30, 2020$1.23M-3.2%
Q1 FY2020CQ4 2019Jan 31, 2020$1.49M-33.7%
Q4 FY2019CQ3 2019Oct 31, 2019$871.19K-64.2%
Q3 FY2019CQ2 2019Jul 31, 2019$1.09M-63.1%
Q2 FY2019CQ1 2019Apr 30, 2019$1.27M+92.3%
Q1 FY2019CQ4 2018Jan 31, 2019$2.25M+188.9%
Q4 FY2018CQ3 2018Oct 31, 2018$2.43M+591.5%
Q3 FY2018CQ2 2018Jul 31, 2018$2.94M+710.6%
Q2 FY2018CQ1 2018Apr 30, 2018$660.19K+53.1%
Q1 FY2018CQ4 2017Jan 31, 2018$777.87K+72.2%
Q4 FY2017CQ3 2017Oct 31, 2017$351.83K-14.9%
Q3 FY2017CQ2 2017Jul 31, 2017$362.97K–
Q2 FY2017CQ1 2017Apr 30, 2017$431.12K–
Q1 FY2017CQ4 2016Jan 31, 2017$451.63K–
Q4 FY2016CQ3 2016Oct 31, 2016$413.49K–

More Anixa Biosciences figures

See a number that looks wrong?